Please use this identifier to cite or link to this item:
Title: Epigenetic Regulation of the PTEN-AKT-RAC1 Axis by G9a Is Critical for Tumor Growth in Alveolar Rhabdomyosarcoma
Authors: Bhat, AV 
Palanichamy Kala, M 
Rao, VK 
Pignata, L
Lim, HJ
Suriyamurthy, S 
Chang, KT 
Lee, VK 
Guccione, E 
Taneja, R 
Issue Date: 1-May-2019
Publisher: American Association for Cancer Research (AACR)
Citation: Bhat, AV, Palanichamy Kala, M, Rao, VK, Pignata, L, Lim, HJ, Suriyamurthy, S, Chang, KT, Lee, VK, Guccione, E, Taneja, R (2019-05-01). Epigenetic Regulation of the PTEN-AKT-RAC1 Axis by G9a Is Critical for Tumor Growth in Alveolar Rhabdomyosarcoma. Cancer research 79 (9) : 2232-2243. ScholarBank@NUS Repository.
Abstract: ©2019 American Association for Cancer Research. Alveolar rhabdomyosarcoma (ARMS) is an aggressive pediatric cancer with poor prognosis. As transient and stable modifications to chromatin have emerged as critical mechanisms in oncogenic signaling, efforts to target epigenetic modifiers as a therapeutic strategy have accelerated in recent years. To identify chromatin modifiers that sustain tumor growth, we performed an epigenetic screen and found that inhibition of lysine methyltransferase G9a significantly affected the viability of ARMS cell lines. Targeting expression or activity of G9a reduced cellular proliferation and motility in vitro and tumor growth in vivo. Transcriptome and chromatin immunoprecipitation-sequencing analysis provided mechanistic evidence that the tumor-suppressor PTEN was a direct target gene of G9a. G9a repressed PTEN expression in a methyltransferase activity-dependent manner, resulting in increased AKT and RAC1 activity. Re-expression of constitutively active RAC1 in G9a-deficient tumor cells restored oncogenic phenotypes, demonstrating its critical functions downstream of G9a. Collectively, our study provides evidence for a G9a-dependent epigenetic program that regulates tumor growth and suggests targeting G9a as a therapeutic strategy in ARMS. SIGNIFICANCE: These findings demonstrate that RAC1 is an effector of G9a oncogenic functions and highlight the potential of G9a inhibitors in the treatment of ARMS.
Source Title: Cancer research
ISSN: 0008-5472
DOI: 10.1158/0008-5472.CAN-18-2676
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
CR Bhat et al preprint.pdf2.15 MBAdobe PDF



Page view(s)

checked on Oct 10, 2019

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.